Pappas Ventures Portfolio

Singular Focus. Superior Results.

4DMT is focused on the discovery and development of targeted, customized and proprietary next-generation AAV gene therapy products for use in patients with severe genetic diseases with high unmet medical need.

x

Achillion is a pharmaceutical company developing treatments for patients with challenging infectious diseases – hepatitis C and resistant bacterial infections. It went public in 2006.

x

Aclara Biosciences went public in 2000, powered by innovative microfluidics technology that automated genetic sequencing and other laboratory functions.

x

Pappas Ventures co-founded Afferent in December 2009, after recognizing a novel mechanism with high potential in the treatment of chronic pain and other areas of substantial medical need.

x

Amplyx was founded on a mission to develop a new class of antifungal medicine that would overcome the severe limitations of today’s therapy options.

x

Anthera is developing and commercializing novel therapeutics to treat serious human illnesses associated with inflammation. It went public in 2010.

x

Arena made its debut as a public company in 2000, with a focus (then and now) on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs).

x

ArgoMed developed a proprietary, water-induced thermotherapy device and technique to address the non-surgical treatment of benign prostatic hyperplasia (BPH).

x

Athersys is a biotechnology company that has established a pipeline of therapeutic product development programs in multiple disease areas based on a stem cell platform called MultiStem®.

x

Balance Therapeutics is a clinical-stage pharmaceutical company developing therapies to improve the lives of patients with debilitating neurological conditions.

x

BaroSense is a medical device company developing minimally invasive devices for the treatment of obesity, the largest global chronic disease in adults.

x

The company pursued DNA-antigen vaccines and oligonucleotides that were specifically designed to promote immune intolerance.

x

BioSyntech focused on biotherapeutic thermogels for regenerative medicine.

x

Bloodhound Technologies created a SaaS (Software as a Service) delivery platform aimed at helping healthcare payers control fraud and waste through a real-time claims processing environment.

x

BrainCells (BCI) is a neurogenesis-based drug discovery and development company targeting novel therapeutics for depression, mood disorders and other central nervous system diseases.

x

Calyx Therapeutics was acquired by Theracos in 2003.

x

CardioDx is a molecular diagnostics company commercializing tools to assist cardiologists in the diagnosis of cardiovascular disease.

x

CeNeRx focused on developing treatments for diseases of the central nervous system.

x

Cequent Pharmaceuticals was acquired by Marina Biotech in 2010.

x

Cerexa was acquired by Forest Laboratories in 2007.

x

Chimerix is developing a range of oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. It went public in April 2013.

x

Cognetix explored the use of snail toxins for the treatment of epilepsy, pain and anesthesia.

x

CoLucid is a clinical stage company developing therapeutics intended for migraine patients who don’t respond well, or at all, to triptan-based drugs.

x

CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases.

x

Developed drugs for irritable bowel syndrome and other gastrointestinal disorders.

x

EBM Solutions was acquired by HealthGate Data Corp. in 2003.

x

Elitra’s assets were acquired by Merck in 2004.

x

Emerald is dedicated to the development of naturally occurring biochemicals for crop enhancement.

x

Envisia focuses on the development of novel ocular therapies.

x

FlowCardia was acquired by C. R. Bard in 2010.

x

Gentis develops novel, biomaterials-based products intended to treat spinal disc disease.

x

IlluminOss has developed a groundbreaking, minimally invasive orthopedic system for the stabilization and treatment of bone fractures.

x

Kezar Life Sciences is a clinical stage company developing novel small molecule therapeutics to treat autoimmune disorders and malignant diseases.

x

LEAD was acquired by BioMarin Pharmaceutical in 2010.

x

LipoScience is building out personalized diagnostic tests for a range of metabolic and other diseases. The company went public in January 2013.

x

Liquidia Technologies uses novel nanoparticle technology platforms to develop innovative healthcare products.

x

Lumena, which was acquired by Shire plc in June 2014, is developing oral therapeutics for adults and children suffering from rare and debilitating liver diseases.

x

Marina is developing and commercializing therapeutic products for rare diseases based on RNA interference (RNAi).

x

Milestone Pharmaceuticals is a cardiovascular drug development company focused on the treatment of transient cardiovascular conditions such as supraventricular tachycardia.

x

Mirati is a biopharmaceutical company that develops novel therapeutics for the treatment of cancer.

x

Mirum is developing a novel approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions.

x

Nereus utilized specialized research out of the Scripps Institution of Oceanography.

x

NuVasive’s broad suite of minimally invasive products covers the breadth of the spine market. NuVasive went public in 2004.

x

In 2010 Optherion entered into a diagnostic alliance with Sequenom and licensed its technology for therapeutic applications to Baxter.

x

Orphomed is a clinical stage biotechnology company focused on the development of best-in-class therapies for the treatment of inadequately-controlled gastrointestinal disorders.

x

Panacos went public via a reverse merger with V.I. Technologies in 2005.

x

Peninsula Pharmaceuticals was acquired by Johnson & Johnson in 2005.

x

Plexigen focused on instrumentation and service for genetic and proteomic testing.

x

Daiichi Sankyo acquired Plexxikon in 2011 for $935 million.

x

Reneo Pharmaceuticals is a clinical-stage start-up company focused on developing treatments for rare metabolic disorders

x

Reprogenesis merged with Ontogeny and Creative BioMolecules to form Curis in 2000.

x

Research Triangle Ventures, a venture capital firm, specialized in investing in seed and early stage technology companies located in North Carolina.

x

Ribometrix is a biotechnology company developing small molecule therapeutics that target RNA to treat human diseases.

x

Rotation Medical has developed a proprietary, minimally invasive rotator cuff implant system for the treatment of rotator cuff disease.

x

Selventa is delivering personalized medicine through computational systems biology for drug discovery and development.

x

Sensys focused on advancing technology for non-invasive blood glucose monitoring.

x

Signase assets were acquired by Systems Medicine Inc. in 2005.

x

Spherics developed an oral delivery technology platform.

x

Syndax is a late stage oncology company using epigenetics, a novel way to control gene regulation, to overcome the problem of resistance seen with oncology treatments.

x

Syntonix was acquired by Biogen Idec in 2007.

x

TargeGen was acquired by Sanofi-Aventis in 2010.

x

TESARO is an oncology-focused biopharmaceutical company developing and providing safer and more effective therapeutics and supportive care products. It went public in 2012.

x

Thrasos is a clinical stage therapeutics company discovering and developing targeted therapies for the prevention and treatment of kidney disease.

x

TYRX, which was acquired by Medtronic, Inc. in early 2014, develops and sells implantable, combination drug and device products using novel biomaterials with a wide variety of clinical applications.

x

Ultragenyx is dedicated to life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases. It went public in January 2014.

x

Variagenics went public in 2000 (Nasdaq) and merged into Hyseq in 2002.

x

VelosBio Inc. is a near-term clinical-stage biopharmaceutical company focused on novel cancer targets.

x

Exelixis acquired X-Ceptor in 2004.

x